Industry insights
Data-driven perspectives on pharmaceutical pricing, market access, and competitive intelligence.
Gene therapy JCA submissions face a distinct methodological test, and
Evaluate a pharmaceutical pricing data provider on the questions your
Joint Clinical Assessment evidence requirements have been tested twice in
Global market access in 2026 has been reshaped by a
The EU Joint Clinical Assessment process produced its first completed
Revlimid’s patent cliff did not follow the conventional script. When
NHS medicines expenditure grew 51.9% between 2019/20 and 2024/25, and
Pharma D2C strategy is no longer a fringe consideration. As
G-BA added benefit determinations shape reimbursement and market access outcomes
